奥林匹斯之门 pp电子奥林匹斯之门

Final Sprint – Shenzhen Cell Valley Successfully Holds Seminar on Application for the Ministry of Science and Technology's National Key R&D Program Project

Date:10-23  Hits:  Belong to:News


图片

Recently, notification was received from the Ministry of Science and Technology that, after months of multiple rounds of review—including preliminary application, letter review, and formal application—the National Key R&D Program project (formerly the 973 Program) titled "Key Technologies and Product Development for Genetically Modified Immune Cell Therapy (Application Demonstration Category)," for which Shenzhen Cell Valley serves as the lead unit, has advanced to the final defense stage. On the morning of October 21, the project leaders and key members of each research task from ten participating units—including Tsinghua University, the University of Science and Technology of China, China Agricultural University, and Peking University Shenzhen Hospital—gathered at Shenzhen Cell Valley to participate in the pre-defense project application seminar.

图片

The meeting was chaired by Professor Shi Yuanyuan, Chief Leader of the project and Chairman of Shenzhen Cell Valley. Distinguished experts attending the seminar included Professor Wan Xiaochun, Chief Expert of National Key R&D Projects and Deputy Director of the Institute of Biomedicine and Biotechnology at the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences; Professor Wu Fenfang, Director of the Central Laboratory of Beijing University of Chinese Medicine Shenzhen Hospital (Longgang); Li Kedeng, Deputy Secretary-General of the China International Science Exchange Foundation; and Dr. Kang Xi, Researcher at the Translational Medicine Center of Shenzhen Bay Laboratory. More than twenty participants attended the meeting, including Professor Wang Jianxun, Chief Scientist of Shenzhen Cell Valley; Professors Cui Hengmi and Zhang Xinyue of Jiangsu Yinovi Biotechnology Co., Ltd.; Director Chen Junhui and Dr. Xu Yanwei of Peking University Shenzhen Hospital; Dr. Li Xiaorui of the College of Biological Sciences at China Agricultural University; and Dr. Ma Yipeng of Shenzhen Innova Immune Co., Ltd., along with other task leaders and key members.

图片

图片

图片

During the seminar, the invited experts provided professional guidance to the project team, offering many valuable suggestions on aspects including research background, domestic and international research status, definition of core concepts, research value, research objectives and content, research plan, innovation highlights, and expected outcomes. The experts fully affirmed the preliminary preparation work of each research task, as well as the topic selection and research value, and provided logically rigorous suggestions for improvement in areas such as focusing on highlight advantages, closely aligning with assessment indicators, ensuring an overall logical closed loop, and expected translation outcomes.

图片

Professor Shi Yuanyuan, Chief Scientist of the project, stated that each research task should greatly cherish the valuable learning opportunity of having experts provide on-site guidance, and should carry out all preparatory work before the project defense in a solid and effective manner in strict accordance with the experts' recommendations.

This seminar promoted exchange and interaction among the participating units of the project team, resolved issues existing in the project application process, and provided a high degree of assurance for efficiently completing the application task and ensuring the smooth defense of the subsequent project.


About Us
Scan to follow our latest newsScan to follow our latest news
Contact Us
400-800-1266

Working hours: Monday to Friday, 9:00-18:00

Contact:Ms. Lai

Email:laijiaqi@jubibj.com

Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

Cell Valley Group is a leading CGT infrastructure platform in China. We capitalize on the strategic window opened by Decree No. 818 to bridge the gap between clinical research and commercialization.

We pioneer the "Hospital to Industry" (H2I) model. Basically, we act as the core partner for hospitals, providing a one-stop solution for new biomedical tech—covering process development, GMP manufacturing, QC, and commercial rollout. Our mission is to push China's CGT sector from pure R&D into a standardized, scalable industry.
 Copyright 粤ICP备2024168379号 互联网药品信息服务资格证书:(粤)-非经营性-2022-0426  Technical Support:YouDian Software